Biotech firm Compass Pathways' operating income beats Q3 analyst expectations

Reuters11-04

Biotech firm Compass Pathways' operating income beats Q3 analyst expectations

Overview

Compass Pathways Q3 net loss driven by non-cash warrant liabilities adjustment
Company accelerates COMP360 commercialization plans by 9-12 months after FDA discussions
Operating income for Q3 beats analyst expectations

Outlook

Company accelerating commercial launch of COMP360 by 9-12 months
COMP360 9-week data from COMP006 expected in Q1 2026
COMP360 26-week data from COMP006 expected in early Q3 2026

Result Drivers

R&D - Expenses were $27.3 million for the three months ended September 30, 2025, compared with $32.9 million during the same period in 2024. T

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$1.44
Q3 Net Income		-$137.71 mln
Q3 Operating Income	Beat	-$40.53 mln	-$42.70 mln (8 Analysts)
Q3 Operating Expenses		$40.53 mln
Q3 Pretax Profit		-$137.94 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Compass Pathways PLC is $14.00, about 57.5% above its November 3 closing price of $5.95

Press Release: ID:nBw3fCSJha

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580738265?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 19:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580738265","market":"fut","top_or_hot":-1,"title":"Biotech firm Compass Pathways' operating income beats Q3 analyst expectations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biotech firm Compass Pathways' operating income beats Q3 analyst expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Compass Pathways Q3 net loss driven by non-cash warrant liabilities adjustment</p></li><li><p>Company accelerates COMP360 commercialization plans by 9-12 months after FDA discussions</p></li><li><p>Operating income for Q3 beats analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company accelerating commercial launch of COMP360 by 9-12 months</p></li><li><p>COMP360 9-week data from COMP006 expected in Q1 2026</p></li><li><p>COMP360 26-week data from COMP006 expected in early Q3 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D - Expenses were $27.3 million for the three months ended September 30, 2025, compared with $32.9 million during the same period in 2024. T</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$1.44</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$137.71 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td><p>Beat</p></td><td><p>-$40.53 mln</p></td><td><p>-$42.70 mln (8 Analysts)</p></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$40.53 mln</p></td><td></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td></td><td><p>-$137.94 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Compass Pathways <a href=\"https://laohu8.com/S/PLC\">PLC</a> is $14.00, about 57.5% above its November 3 closing price of $5.95</p></li></ul><p>Press Release: <span>ID:nBw3fCSJha</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech firm Compass Pathways' operating income beats Q3 analyst expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech firm Compass Pathways' operating income beats Q3 analyst expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 19:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biotech firm Compass Pathways' operating income beats Q3 analyst expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Compass Pathways Q3 net loss driven by non-cash warrant liabilities adjustment</p></li><li><p>Company accelerates COMP360 commercialization plans by 9-12 months after FDA discussions</p></li><li><p>Operating income for Q3 beats analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company accelerating commercial launch of COMP360 by 9-12 months</p></li><li><p>COMP360 9-week data from COMP006 expected in Q1 2026</p></li><li><p>COMP360 26-week data from COMP006 expected in early Q3 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D - Expenses were $27.3 million for the three months ended September 30, 2025, compared with $32.9 million during the same period in 2024. T</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$1.44</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$137.71 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td><p>Beat</p></td><td><p>-$40.53 mln</p></td><td><p>-$42.70 mln (8 Analysts)</p></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$40.53 mln</p></td><td></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td></td><td><p>-$137.94 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Compass Pathways <a href=\"https://laohu8.com/S/PLC\">PLC</a> is $14.00, about 57.5% above its November 3 closing price of $5.95</p></li></ul><p>Press Release: <span>ID:nBw3fCSJha</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMPS","symbol_name":"COMPASS Pathways plc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL1N3WG0FE:1","article_id":"2580738265","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580738265","pubTimestamp":1762256849,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biotech firm Compass Pathways' operating income beats Q3 analyst expectationsOverviewCompass Pathways Q3 net loss driven by non-cash warrant liabilities adjustmentCompany accelerates COMP360 commercia","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMPS":"COMPASS Pathways plc","BK4139":"生物科技"},"translate_title":"生物技术公司Compass Pathways第三季度营业收入超出分析师预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPS":0.9},"content_text":"Biotech firm Compass Pathways' operating income beats Q3 analyst expectationsOverviewCompass Pathways Q3 net loss driven by non-cash warrant liabilities adjustmentCompany accelerates COMP360 commercialization plans by 9-12 months after FDA discussionsOperating income for Q3 beats analyst expectationsOutlookCompany accelerating commercial launch of COMP360 by 9-12 monthsCOMP360 9-week data from COMP006 expected in Q1 2026COMP360 26-week data from COMP006 expected in early Q3 2026Result DriversR&D - Expenses were $27.3 million for the three months ended September 30, 2025, compared with $32.9 million during the same period in 2024. TKey DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$1.44Q3 Net Income-$137.71 mlnQ3 Operating IncomeBeat-$40.53 mln-$42.70 mln (8 Analysts)Q3 Operating Expenses$40.53 mlnQ3 Pretax Profit-$137.94 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Compass Pathways PLC is $14.00, about 57.5% above its November 3 closing price of $5.95Press Release: ID:nBw3fCSJhaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580738265","isCrawlerRequest":true}